4,4-difluoro-1-(4-methoxy-phenyl)-butane-1,3-dione | 189347-40-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4,4-difluoro-1-(4-methoxy-phenyl)-butane-1,3-dione
• 英文别名: 4,4-Difluoro-1-(4-methoxyphenyl)butane-1,3-dione
• CAS: 189347-40-8
• 化学式: C₁₁H₁₀F₂O₃
• mdl: MFCD03419781
• 分子量: 228.195
• InChiKey: IHLFDMHYDXVXHM-UHFFFAOYSA-N

物化性质

• 沸点：
  338.0±37.0 °C(Predicted)
• 密度：
  1.224±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  4,4-difluoro-1-(4-methoxy-phenyl)-butane-1,3-dione 在 正丁基锂 、 硫酸 、 盐酸羟胺 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 (5-(difluoromethyl)-3-(4-methoxyphenyl)isoxazol-4-yl)(phenyl)methanol
  参考文献：
  名称：

  3-芳基-5-二氟甲基-异恶唑在醛中的区域选择性亲核加成

  摘要：

  制备了一系列5-二氟甲基-异恶唑2，并研究了它们对醛的区域选择性亲核加成。已经发现，在LDA作为提供大空间位阻的碱的存在下，醛与5-二氟甲基-异恶唑的亲核二氟甲基化可以有效且独特地实现。相反，当使用n- BuLi作为碱时，以适中的收率交替提供3,4,5-三取代的5-二氟甲基异恶唑作为唯一产物。

  DOI：

  10.1016/j.jfluchem.2012.11.003
• 作为产物：
  描述：

  二氟乙酸乙酯 、 对甲氧基苯乙酮 在 sodium methylate 作用下， 以 乙二醇二甲醚 为溶剂， 生成 4,4-difluoro-1-(4-methoxy-phenyl)-butane-1,3-dione
  参考文献：
  名称：

  Discovery of a potent, selective and orally active canine COX-2 inhibitor, 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl-pyridine

  摘要：

  Structure-activity relationship (SAR) studies of 2-[3-di(and tri)fluoromethyl-5-arylpyrazol-1-yl]-5-methanesulfonylpyridine derivatives for canine COX enzymes are described. This led to the identification of 12a as a lead candidate for further progression. The in vitro and in vivo activity of 12a for the canine COX-2 enzyme as well as its in vivo efficacy and pharmacokinetic properties in dog are highlighted. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.10.004

文献信息

• Highly Regioselective Synthesis of 1-Aryl-3,4,5-Substituted Pyrazoles
  作者：Francis Gosselin、Paul O’Shea、Robert Webster、Robert Reamer、Richard Tillyer、Edward Grabowski

  DOI：10.1055/s-2006-956487

  日期：——

  A highly regioselective synthesis of 1-aryl-3,4,5-substituted pyrazoles based on the condensation of 1,3-diketones with arylhydrazines is described. The reaction proceeds at room temperature in N,N-dimethylacetamide and furnishes pyrazoles in 59-98% yields.

  描述了基于 1,3-二酮与芳基肼缩合的 1-芳基-3,4,5-取代吡唑的高度区域选择性合成。该反应在室温下在 N,N-二甲基乙酰胺中进行，并以 59-98% 的产率提供吡唑。
• [EN] PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRAZOLO-PYRIMIDINE ET D'IMIDAZO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005040171A1

  公开（公告）日：2005-05-06

  The present invention relates to novel pyrazolo- and imidazo-pyrimidine derivatives of formula (I) wherein A, D, E, L, M, Q, R1, R2 and R3 are as defined in the description and claims and to processes for their preparation, pharmaceutical compositions containing said derivatives and their use in the prevention and treatment of diseases.

  本发明涉及公式（I）中的新型吡唑啉和咪唑嘧啶衍生物，其中A、D、E、L、M、Q、R1、R2和R3如描述和索赔中所定义，并涉及其制备方法、含有所述衍生物的药物组合物以及它们在预防和治疗疾病中的用途。
• Studies on Anti-inflammatory Agents. V. Synthesis and Pharmacological Properties of 3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-(4-(methylsulfinyl)phenyl)pyrazole and Related Compounds.
  作者：Kiyoshi TSUJI、Nobukiyo KONISHI、Glen W. SPEARS、Takashi OGINO、Katsuya NAKAMURA、Takashi TOJO、Takehiro OCHI、Fumio SHIMOJO、Hachiro SENOH、Masaaki MATSUO

  DOI：10.1248/cpb.45.1475

  日期：——

  these compounds were evaluated by using the adjuvant arthritis and Randall-Selitto assays in rats, and the structure-activity relationships were studied. The optimal compound was 3-(difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyraz ole (10) with oral ED50 values of 0.31 and 2.6 mg/kg on adjuvant-induced arthritis and carrageenin-induced foot edema, respectively. Compound 10 showed

  制备了一系列带有亲水取代基的新型1，5-二苯基吡唑衍生物。通过在大鼠中使用佐剂关节炎和Randall-Selitto试验评估了这些化合物的抗炎和镇痛活性，并研究了其构效关系。最佳化合物为3-（二氟甲基）-1-（4-甲氧基苯基）-5- [4-（甲基亚磺酰基）苯基]吡唑（10），口服佐剂诱发的关节炎时的ED50值为0.31和2.6 mg / kg。角叉菜胶引起的足部水肿。在Randall-Selitto分析中，化合物10不仅对发炎的爪显示镇痛活性，而且还对正常爪显示镇痛活性（分别为ED30 = 0.55和1.8 mg / kg），此外，化合物10在尾巴捏制试验中有效（ED50 = 21毫克/千克）与吗啡类似。
• Pyrazolo-pyridine
  申请人：Wichmann Juergen

  公开号：US20050130992A1

  公开（公告）日：2005-06-16

  The present invention relates to novel pyrazolo- and imidazo-pyrimidine derivatives of formula I wherein A, D, E, L, M, Q, R 1 , R 2 and R 3 are as defined hereinabove. The present invention also relates to a process for their preparation, a pharmaceutical composition containing said derivatives and a method of treating or preventing acute or chronic neurological disorder comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of at least one such derivatives. These disorders include acute and chronic disorders

  本发明涉及式I的新型吡唑并咪唑嘧啶衍生物，其中A、D、E、L、M、Q、R1、R2和R3如上所定义。本发明还涉及它们的制备方法，含有该衍生物的药物组合物以及治疗或预防急性或慢性神经障碍的方法，包括向需要该治疗的患者给予含有至少一种该类衍生物的治疗剂量的药物组合物。这些障碍包括急性和慢性障碍。
• Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors
  申请人：Hoffmann-La Roche Inc.

  公开号：US07514443B2

  公开（公告）日：2009-04-07

  The present invention relates to novel pyrazolo- and imidazo-pyrimidine derivatives of formula I wherein A, D, E, L, M, Q, R1, R2 and R3 are as defined hereinabove. The present invention also relates to a process for their preparation, a pharmaceutical composition containing said derivatives and a method of treating or preventing acute or chronic neurological disorder comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of at least one such derivatives. These disorders include acute and chronic disorders.

  本发明涉及一种新型嘧唑并咪唑嘧啶衍生物，其化学式为I，其中A、D、E、L、M、Q、R1、R2和R3如上所定义。本发明还涉及一种制备它们的方法，包含所述衍生物的制药组合物以及治疗或预防急性或慢性神经系统疾病的方法，包括向需要此类治疗的患者给予包含至少一种这样的衍生物的治疗有效量的制药组合物。这些疾病包括急性和慢性疾病。